Source: GlobalData
Ionis’ Olezarsen to achieve global sales of approximately $849 million by 2032, forecasts GlobalData
Posted in Pharma
Ionis Pharmaceuticals has announced positive topline results from the ESSENCE study evaluating Olezarsen in individuals with moderate hypertriglyceridemia who are at risk of atherosclerotic cardiovascular disease (ASCVD). Upon approval, the drug is projected to achieve global sales of approximately $849 million by 2032, according to GlobalData, a leading data and analytics company.
The study met its primary endpoint, demonstrating a statistically significant, placebo-adjusted reduction in triglyceride levels of 61% and 58% at six months with the 80mg and 50mg monthly doses, respectively (p
Dr Shireen Mohammad, Senior Cardiovascular and Metabolic Disorders Analyst at GlobalData, concludes: “This data is highly anticipated and will be crucial in determining the drug’s efficacy and safety profile. Positive results could pave the way for regulatory approval and establish olezarsen as a first-in-class treatment option for patients with limited alternatives.”
Olezarsen is an antisense oligonucleotide (ASO) designed to selectively inhibit the expression of the APOC3 gene. By decreasing the production of apolipoprotein C-III (ApoC-III)—a protein that hinders triglyceride metabolism—olezarsen promotes the efficient breakdown and clearance of triglyceride-rich lipoproteins. This leads to a marked reduction in plasma triglyceride levels, positioning olezarsen as a promising treatment for severe hypertriglyceridemia, familial chylomicronemia syndrome (FCS), and other dyslipidemias.
Key opinion leaders (KOLs) interviewed by GlobalData emphasized a significant unmet need for effective treatments targeting rare genetic lipid disorders, particularly FCS and familial hypercholesterolemia (FH).
Dr Mohammad adds: “Notably, there are currently no FDA-approved therapies for FCS, underscoring the urgency for new options that can lower triglyceride levels and mitigate associated complications. With its targeted mechanism and encouraging data, olezarsen has the potential to address this therapeutic gap.”
Pivotal Phase III results from the ongoing CORE and CORE2 trials, which are evaluating olezarsen for the treatment of severe hypertriglyceridemia (sHTG), are expected in Q3 2025.